NewsBenzingaVor Bio、RemeGen提携先によるテリタシセプトの第3相試験データを発表、48週間で参加者の95%以上がMG-ADLスコアを少なくとも5ポイント改善 Vor Bio、RemeGen提携先によるテリタシセプトの第3相試験データを発表、48週間で参加者の95%以上がMG-ADLスコアを少なくとも5ポイント改善 Benzinga 2026.09.29 12:07 (GMT+0) Open on Benzinga Other news Freedom Broker Maintains Buy on XPeng, Lowers Price Target to $20 Plug Power Shares Slide Toward 52-Week Low Despite New 280-MW Texas Deal Nvidia Vs. Anthropic: Can the AI IPO Challenge Nvidia’s Dominance Across ETFs? Freedom Broker Maintains Buy on Allot, Lowers Price Target to $12.7 Freedom Broker Upgrades M-Tron Industries to Buy, Lowers Price Target to $84 As decision model use skyrockets, is customization is the next frontier?